ARCHIMED
ARCHIMED is a global private equity firm founded in 2014 and headquartered in Lyon, France, focused exclusively on healthcare industries. It manages around 8 billion across various funds and invests in profitable small and midsize healthcare companies worldwide.
Key facts
Recent exits
Coverage notes
6 funds tracked, 54 portfolio companies (39 active · 15 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
54 companiesFunds & portfolio
Every fund ARCHIMED has raised, with its portfolio companies. Hand-checked from public filings.
MED RiseBuyout2024 · 2yr€400M12 active
Unrealized
12 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| HealthTech |  US | 2025 | |
| Biotech | Canada | 2024 | |
| HealthTech | US | 2024 | |
| Healthcare |  France | 2025 | |
| Biotech |  Switzerland | 2025 | |
| MedTech | France | 2024 | |
| HealthTech | France | 2025 | |
| Pharma |  Spain | 2026 | |
| MedTech | US | 2024 | |
| HealthTech | South Korea | 2024 | |
| MedTech | US | 2024 | |
| MedTech | US | 2025 |
US· Entry 2025US· Entry 2024France· Entry 2025Switzerland· Entry 2025France· Entry 2024France· Entry 2025Spain· Entry 2026US· Entry 2024US· Entry 2024US· Entry 2025MED Platform IIBuyout2022 · 4yr€3.5B7 active
Unrealized
7 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| MedTech | US | 2025 | |
| Pharma | Canada | 2022 | |
| – | – | 2026 | |
| HealthTech | US | 2023 | |
| MedTech | US | 2022 | |
| Pharma | US | 2023 | |
| HealthTech |  Italy | 2023 |
US· Entry 2025US· Entry 2023US· Entry 2022US· Entry 2023Italy· Entry 2023MED IIIBuyout2021 · 5yr€650M12 active · 1 realized
Unrealized
12 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Pharma | US | 2021 | |
| MedTech | Czech Republic | 2025 | |
| MedTech | Italy | 2021 | |
| Biotech |  Germany | 2021 | |
| Biotech | Germany | 2021 | |
| HealthTech |  Denmark | 2025 | |
| MedTech | US | 2022 | |
| Biotech | Germany | 2022 | |
| HealthTech | Canada | 2021 | |
| Biotech | Switzerland | 2021 | |
| Pharma | HQ Spain / Global presence | 2021 | |
| HealthTech | US | 2022 |
US· Entry 2021Italy· Entry 2021Germany· Entry 2021Germany· Entry 2021Denmark· Entry 2025US· Entry 2022Germany· Entry 2022Switzerland· Entry 2021US· Entry 2022Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech |  Belgium | 2021 | 2022 | Trade Sale | – |
MED Platform IBuyout2019 · 7yr€1.5B3 active · 5 realized
Unrealized
3 held
Realized
5 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| MedTech | US | 2020 | 2024 | Secondary | |||
| HealthTech | US | 2020 | 2026 | Trade Sale | – | ||
| MedTech | Italy | 2019 | 2023 | Trade Sale | |||
| MedTech |  UK | 2019 | 2026 | Secondary | – | ||
| MedTech |  Austria | 2019 | 2022 | Trade Sale |
MED IIBuyout2017 · 9yr€315M4 active · 1 realized
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Healthcare | France | 2025 | |
| Biotech | France | 2018 | |
| Biotech | France | 2018 | |
| MedTech | The Netherlands | 2018 |
France· Entry 2025France· Entry 2018France· Entry 2018MED IBuyout2014 · 12yr€150M1 active · 8 realized
Realized
8 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| MedTech | Italy | 2014 | 2025 | Trade Sale | |||
| Pharma | UK | 2015 | 2024 | Trade Sale | – | ||
| HealthTech | France | 2016 | 2023 | Trade Sale | |||
| MedTech | France | 2016 | 2023 | Trade Sale | – | ||
| HealthTech | France | 2016 | 2017 | Trade Sale | |||
| Biotech | France | 2016 | 2023 | Trade Sale | |||
| HealthTech | Italy | 2015 | 2024 | Secondary | |||
| HealthTech | UK | 2015 | 2024 | Trade Sale |
Saved GPs appear in your watchlist, one click from your workspace.
About ARCHIMED
ARCHIMED is a French private equity firm exclusively dedicated to healthcare with €9.0 billion of assets under management as of December 2024, founded in 2014 and headquartered in Lyon with additional offices in Paris, London, New York, Milan and Munich. The firm is one of the few European private equity platforms focused entirely on healthcare verticals, providing depth of sector expertise across pharmaceuticals, medical technologies and life sciences services that generalist mid-cap funds cannot match.
Investment thesis
ARCHIMED targets European and selectively North American healthcare companies across MedTech, Pharma services, HealthTech, Biotech and broader healthcare services, deploying capital through dedicated flagship funds (MED Platform I, II and follow-on vintages) plus a Eureka small-cap programme for emerging healthcare companies. Equity ticket sizes typically range from €50 million to €300 million for the flagship strategy, with majority and significant minority equity positions held through five to seven year horizons. The healthcare sector-exclusive focus enables deep operational expertise, regulatory navigation and management team networks unique to medical-device, pharma and HealthTech businesses.
Recent activity
Recent realised exits include Ametris / ActiGraph (HealthTech, 2026), CARSO (MedTech, 2025), Citieffe (MedTech, 2025), DIESSE (MedTech, 2025), Ad-Tech Medical Instrument (MedTech, 2024) and Deallus (Pharma, 2024), demonstrating strong distribution momentum across the medical device and pharma services verticals. The platform tracks 6 funds, 36 active portfolio companies and 15 realised exits, with ongoing deployment from the latest flagship vintage across European and North American healthcare targets. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€7.0B
France·€11.2B
France·€6.7B
France·€6.5B
France·€11.6B
France·€6.0B
France·€5.1B
France·€5.0B
France·€13.2B
France·€4.3B
France·€4.2B
France·€4.0BGet the full picture on ARCHIMED.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in